Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with evidence of vascular disease are at increased risk for subsequent vascular events despite effective use of statins to lower the low-density lipoprotein (LDL) cholesterol level. Niacin lowers the LDL cholesterol level and raises the high-density lipoprotein (HDL) cholesterol level, but its clinical efficacy and safety are uncertain. METHODS: After a prerandomization run-in phase to standardize the background statin-based LDL cholesterol-lowering therapy and to establish participants' ability to take extended-release niacin without clinically significant adverse effects, we randomly assigned 25,673 adults with vascular disease to receive 2 g of extended-release niacin and 40 mg of laropiprant or a matching placebo daily. The primary outcome was the first major vascular event (nonfatal myocardial infarction, death from coronary causes, stroke, or arterial revascularization). RESULTS: During a median follow-up period of 3.9 years, participants who were assigned to extended-release niacin-laropiprant had an LDL cholesterol level that was an average of 10 mg per deciliter (0.25 mmol per liter as measured in the central laboratory) lower and an HDL cholesterol level that was an average of 6 mg per deciliter (0.16 mmol per liter) higher than the levels in those assigned to placebo. Assignment to niacin-laropiprant, as compared with assignment to placebo, had no significant effect on the incidence of major vascular events (13.2% and 13.7% of participants with an event, respectively; rate ratio, 0.96; 95% confidence interval [CI], 0.90 to 1.03; P=0.29). Niacin-laropiprant was associated with an increased incidence of disturbances in diabetes control that were considered to be serious (absolute excess as compared with placebo, 3.7 percentage points; P<0.001) and with an increased incidence of diabetes diagnoses (absolute excess, 1.3 percentage points; P<0.001), as well as increases in serious adverse events associated with the gastrointestinal system (absolute excess, 1.0 percentage point; P<0.001), musculoskeletal system (absolute excess, 0.7 percentage points; P<0.001), skin (absolute excess, 0.3 percentage points; P=0.003), and unexpectedly, infection (absolute excess, 1.4 percentage points; P<0.001) and bleeding (absolute excess, 0.7 percentage points; P<0.001). CONCLUSIONS: Among participants with atherosclerotic vascular disease, the addition of extended-release niacin-laropiprant to statin-based LDL cholesterol-lowering therapy did not significantly reduce the risk of major vascular events but did increase the risk of serious adverse events. (Funded by Merck and others; HPS2-THRIVE ClinicalTrials.gov number, NCT00461630.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the EU, treatment with niacin was stopped after the AIM-HIGH and HPS2-THRIVE trials showed no improvement in MACE and an increased occurrence of undesirable side effects [123, 124].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [124]
In the citing paper
“Nonetheless, these studies also did not prospectively enroll patients with elevated TG levels despite statin therapy,6, 12, 13, 14, 15”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [14]
In the citing paper
“Prior CV outcome studies that administered therapies with TG‐lowering effects (niacin or fenofibrate) on top of statin therapy did not reach their primary endpoints.”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [14]
In the citing paper
“and an increased incidence of new-onset diabetes (absolute excess, 1.3 percentage points; P < 0.001) and disturbances in diabetes management among those with diabetes in the HPS2-THRIVE trial in those on combination therapy (161).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [161]
In the citing paper
“Large clinical trials, including the Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) and Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) trials, failed to demonstrate a benefit of adding niacin to individuals on appropriate statin therapy.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [161]
20 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Prostaglandins and Inflammation
Ricciotti, E., & FitzGerald, G. A. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.207449 · Cited by 3,803
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Beta blockade during and after myocardial infarction: An overview of the randomized trials
Yusuf, S., Peto, R., Lewis, J., Collins, R., & Sleight, P. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(85)80003-7 · Cited by 3,205
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Clofibrate and Niacin in Coronary Heart Disease
(1975) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1975.03240160024021 · Cited by 1,747
Cited by
Items 1,101–1,200 of 1,676
Whyte, M. (2019) · JRSM Cardiovascular Disease · doi:10.1177/2048004019869736 · Cited by 5
“This was followed three years later by the publication of the Heart Protection Study 2 Treatment of HDL to Reduce the Incidence of Vascular Events.24 This study evaluated extended-release niacin in combination with laropiprant (a prostaglandin receptor antagonist to reduce facial flushing) to effective statin-based LD…”
Kwon, T., Jang, A. Y., Kim, S., Hong, Y. J., Bae, J., Lee, S. Y., Kim, S., & Han, S. H. (2020) · Trials · doi:10.1186/s13063-020-04291-5 · Cited by 6
“combination therapy was associated with an increased risk of adverse effects, such as new-onset diabetes mellitus, diabetic complications, gastrointestinal problems, bleeding, and infection, and a lack of improvement in clinical outcomes, thereby limiting its use [24, 25].”
BackgroundOmega-3 fatty acid therapy for cardiovascular disease: justified or not?
Maki, K. C., & Dicklin, M. R. (2020) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000741 · Cited by 6
Ferrières, J., Lautsch, D., Bramlage, P., Horack, M., Baxter, C. A., Ambegaonkar, B. M., Toth, P. P., Poh, K. K., Ferrari, G. M. D., & Gitt, A. K. (2020) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2020.05.013 · Cited by 7
Lan, N. S. R., Burns, K. A., Bell, D. A., & Watts, G. F. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000594 · Cited by 6
Chan, D. C., Pang, J., & Watts, G. F. (2016) · Springer eBooks · doi:10.1007/978-3-319-11251-0_30 · Cited by 11
Leatherman, S. M., Ferguson, R. E., Hau, C., Harrington, K. M., Granowitz, C. B., Philip, S., Toth, P. P., Bhatt, D. L., & Boden, W. E. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.982815 · Cited by 7
Approach to the Patient with Dyslipidemia
Feingold, K. R. (2015) · Europe PMC (PubMed Central) · Cited by 7
Włodarczyk, M., Wrzosek, M., Nowicka, G., & Jabłonowska-Lietz, B. (2016) · Archives of Medical Science · doi:10.5114/aoms.2016.60870 · Cited by 6
Lipoprotein and Lipid Metabolism
Hegele, R. A. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-383834-6.00100-2 · Cited by 12
Huangfu, G., Chan, D. C., Pang, J., Jaltotage, B., Watts, G. F., Lan, N. S. R., Bell, D. A., Ihdayhid, A. R., Ayonrinde, O. T., & Dwivedi, G. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.02.013 · Cited by 9
Kaye, A. D., COFFMAN, G. D., Mashaw, S. A., Thomassen, A. S., Broocks, K. M., Anwar, A. I., Ahmadzadeh, S., & Shekoohi, S. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47060400 · Cited by 6
Henry, D., Baugé, E., Staels, B., & Lalloyer, F. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100086 · Cited by 5
Lepodisiran: Effects on Lipoprotein(a) and Cardiovascular Outcomes in Adults with Elevated Lp(a)
Kattamuri, L. P. V., Sharma, K., & Mukherjee, D. (2025) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/011871529x390148250908045359 · Cited by 6
Increased Cardiovascular Risk in Young Patients with CKD and the Role of Lipid-Lowering Therapy
Krátký, V., Valeriánová, A., Hrušková, Z., Tesař, V., & Malík, J. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01191-w · Cited by 6
“So far, niacin has not shown any additional CVD benefit on top of statin [49, 50].”
Ranasinghe, S., Cui, Y., Muhyieddeen, A., Obrutu, O., Wei, J., Gulati, M., Bittner, V., Reís, S. E., Handberg, E. M., Pepine, C. J., et al. (2024) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2024.100376 · Cited by 6
Garagoli, F., Masson, W. M., & Barbagelata, L. (2024) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2024.108020 · Cited by 9
Lian, P., Zhu, W.-Q., Zhao, W.-X., Huang, P., Ran, J., Tang, Y., Huang, X., & Li, R. (2024) · Clinica Chimica Acta · doi:10.1016/j.cca.2024.119982 · Cited by 5
Hashem, C., Altin, S. E., Guyton, J. R., & Boden, W. E. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.12.009 · Cited by 7
Quo Vadis after AEGIS: New Opportunities for Therapies Targeted at Reverse Cholesterol Transport?
Lan, N. S. R., & Watts, G. F. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01281-3 · Cited by 7
“…these recent Mendelian randomisation studies may explain why clinical trials have not shown significant reductions in ASCVD events with therapies that specifically increase HDL-cholesterol concentrations, without significantly altering the distribution of HDL particles and their properties [6–10].”
Comprehensive evaluation of siRNA therapeutics on Lp(a): A network meta‐analysis
Liu, S., Wang, X., Hu, J., Zhao, C., & Qin, X. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16355 · Cited by 9
“7,17,18 While apheresis, though effective, is restricted by high costs and limited accessibility.”
Emerging drugs for hyperlipidaemia: an update
Florentin, M., Kostapanos, M. S., Kei, A. A., & Elisaf, M. (2014) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2014.976553 · Cited by 5
“Specifically, the addition of nicotinic acid/ laropiprant to simvastatin (± ezetimibe) not only did not reduce cardiovascular outcomes in patients with established CVD, but was associated with excess adverse events [59,60].”
BackgroundManaging Residual Risk After Myocardial Infarction Among Individuals with Low Cholesterol Levels
Colantonio, L. D., & Bittner, V. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2015.09.011 · Cited by 6
Role of Lipoprotein(a) in Cardiovascular Disease: A Review of Clinical Practice
Minami, Y., Kinoshita, D., Muramatsu, Y., Nagata, T., & Ako, J. (2022) · Journal of Asian Pacific Society of Cardiology · doi:10.15420/japsc.2021.31 · Cited by 5
English, C. J., Lohning, A. E., Mayr, H. L., Jones, M., & Reidlinger, D. P. (2022) · BioFactors · doi:10.1002/biof.1928 · Cited by 7
HDL-Based Therapy: Vascular Protection at All Stages
Poznyak, A. V., Sukhorukov, V. N., Eremin, I. I., Nadelyaeva, I. I., Gutyrchik, N. A., & Orekhov, A. N. (2023) · Biomedicines · doi:10.3390/biomedicines11030711 · Cited by 7
Sæther, J. C., Vesterbekkmo, E. K., Gigante, B., Giskeødegård, G. F., Bathen, T. F., Follestad, T., Wiseth, R., Madssen, E., & Bye, A. (2023) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2023.101215 · Cited by 7
Wang, Z., Zhang, X., Qu, Y., Zhang, S., Chen, Y., Chen, X., Qi, X., Liu, P., Liu, S., Jiang, S., et al. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01838-8 · Cited by 8
Lipid clinical trials with special reference to Indian population
Aseem Basha, M., & Ramakrishnan, S. (2024) · Indian Heart Journal · doi:10.1016/j.ihj.2024.02.003 · Cited by 7
“4,40 On the contrary, there was increased frequency of serious adverse effects and is no longer used as an add-on to baseline statin therapy.”
BackgroundCardoso-Saldaña, G. C., Antonio‐Villa, N. E., Martínez-Alvarado, M. R., González-Salazar, M. D. C., & Posadas‐Sánchez, R. (2024) · BMC Endocrine Disorders · doi:10.1186/s12902-024-01642-0 · Cited by 6
“Moreover, several clinical [7–9] and genetic studies [4] have not been able to demonstrate the cardioprotective role of high HDL-C levels.”
BackgroundNiacin, food intake and cardiovascular effects
Guyton, J. R., & Boden, W. E. (2024) · Nature Medicine · doi:10.1038/s41591-024-03220-2 · Cited by 5
Lin, L., Chen, S., Zhang, C., Li, L., Chen, Y., Li, D., Cai, Q., Zhou, X., & Yang, F. (2024) · Scientific Reports · doi:10.1038/s41598-024-79986-9 · Cited by 5
Hu, M., Yang, Y., Chan, P., & Tomlinson, B. (2015) · Pharmacogenomics · doi:10.2217/pgs.15.79 · Cited by 5
Brown, W. V., Foody, J. M., Zieve, F. J., Tomassini, J. E., Shah, A. K., & Tershakovec, A. M. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.10.002 · Cited by 5
Lipids and cardiovascular disease 3 Triglycerides and cardiovascular disease
Nordestgaard, B. G., & Varbo, A. (2014) · Cited by 5
Current Consensus and Controversies in Guidelines for Lipid and Hypertension Management in Diabetes
Ganda, O. P., & Mitri, J. (2016) · Current Cardiology Reports · doi:10.1007/s11886-016-0790-1 · Cited by 6
An update on trials of novel lipid-lowering drugs
Wierzbicki, A. S., Reynolds, T., & Viljoen, A. (2018) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000518 · Cited by 5
Cardiovascular outcomes trials with non-statin lipid-lowering drugs in diabetes
Naeem, F., McKay, G. A., & Fisher, M. (2018) · British Journal of Diabetes · doi:10.15277/bjd.2018.180 · Cited by 6
Feingold, K. R. (2020) · Europe PMC (PubMed Central) · Cited by 11
Warren, R. A., Carew, A. S., Andreou, P., Levy, A. P., Sapp, J. L., Lache, O., Ginsberg, H. N., Rimm, E. B., Herman, C. R., Kirkland, S., et al. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.030288 · Cited by 5
Reconstituted HDL ameliorated renal injury of diabetic kidney disease in mice
Tao, Y., Lacko, A. G., Sabnis, N. A., et al. (2024) · Physiological Reports · doi:10.14814/phy2.16179 · Cited by 5
Kastelein, J. J. P. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61332-5 · Cited by 7
Zhong, Y., Jiang, C., Cheng, K. K., Zhang, W., Jin, Y., Lam, T. H., Woo, J., Leung, G. M., & Schooling, C. M. (2016) · Annals of Epidemiology · doi:10.1016/j.annepidem.2016.07.005 · Cited by 5
What role for lipoprotein(a) in clinical practice?
Nicholls, S. J., & Psaltis, P. J. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30063-3 · Cited by 5
Beyond Statins: Who and When to Prescribe?
Ganda, O. P. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1087-0 · Cited by 6
Treatment of Dyslipidemia in Elderly Patients With Coronary Heart Disease
Toth, P. P. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.06.1356 · Cited by 5
Levinson, S. S. (2017) · Clinica Chimica Acta · doi:10.1016/j.cca.2017.11.001 · Cited by 5
Streja, E., Streja, D. A., Soohoo, M., Kleine, C., Hsiung, J., Park, C., & Moradi, H. (2018) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2018.05.007 · Cited by 5
The Role of Niacin in the Management of Dyslipidemia
Keenan, J. M. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.81725 · Cited by 5
Zheng, W., Zhang, J., Huang, Y., Wang, S., Gao, X., Yang, Z., Zong, Y., & Yang, Z. (2024) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-024-00694-6 · Cited by 5
Lo, J., Melhorn, S. J., Kee, S., Olerich, K. L. W., Huang, A., Yeum, D., Beiser, A., Seshadri, S. S., DeCarli, C. S., & Schur, E. A. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.039463 · Cited by 5
Association of high-density lipoprotein cholesterol with the top 10 causes of death
Shi, S., Lin, Z., Song, Y., Ye, Z., Song, C., & Dou, K. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf749 · Cited by 8
Existing and Potential Therapeutic Strategies for Lowering Lipoprotein(a) Levels: An Update
Domański, I., Kozieł, A., Domański, J., & Trocha, M. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15062179 · Cited by 4
Lipoprotein(a) as a Predictive Biomarker and Therapeutic Target for Acute Coronary Syndromes
Dimitroglou, Y., Aggeli, C., Theofilis, P., Tsioufis, P., Oikonomou, E. K., Tsioufis, K. P., & Tousoulis, D. (2023) · Current Pharmaceutical Design · doi:10.2174/1381612829666230601155001 · Cited by 5
Sabbour, H. M., Bhatt, D. L., Elhenawi, Y., Aljaberi, A. K., Bennani, L., Fiad, T. M., Hasan, K. Y., Hashmani, S., Hijazi, R. A., Khan, Z., et al. (2024) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-023-07519-z · Cited by 4
“…laropiprant in the 2011 Atherothrombosis Intervention in Metabolic Syndromes with Low HDL/High Triglycerides and Impact on Global Health Outcomes (AIM-HIGH) trial [64] and the 2014 Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) [65], respectively.”
Andersson, D. P., Littmann, K., Kindborg, G., Eklund, D., Sejersen, K., Yan, J., Hogling, D. E., Parini, P., & Brinck, J. W. (2024) · European Heart Journal Open · doi:10.1093/ehjopen/oeae010 · Cited by 4
“…treatment to reduce cardiovascular risk, the prospective outcome trials with peroxisome proliferator-activated receptors alfa agonist (i.e. 21 The only successful outcome trial targeting individuals with hTG in the prevention of cardiovascular outcomes could not show an association…”
BackgroundAgreement Between Mega-Trials and Smaller Trials: A Systematic Review and Meta-Research Analysis
Kastrati, L., Raeisi‐Dehkordi, H., Llanaj, E., Quezada‐Pinedo, H. G., Khatami, F., Ahanchi, N. S., Llane, A., Meçani, R., Muka, T., & Ioannidis, J. P. A. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.32296 · Cited by 7
Zhou, Y., Luo, R., Blais, J. E., Tan, K. C. B., Lui, D. T. W., Yiu, K. H., Lai, F. T. T., Wan, E. Y. F., Cheung, C., Wong, I. C. K., et al. (2025) · npj Digital Medicine · doi:10.1038/s41746-025-01951-1 · Cited by 12
Severe hypertriglyceridemia. Clinical characteristics and therapeutic management
Masson, W. M., Rossi, E., Siniawski, D. A., Damonte, J. I., Halsband, A., Barolo, R., & Scaramal, M. (2018) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2018.08.003 · Cited by 3
The Role of Physical Activity and Exercise in Preventive Cardiology
Thompson, P. D. (2022) · Medical Clinics of North America · doi:10.1016/j.mcna.2021.11.002 · Cited by 8
Lu, X., Zhang, L., Li, S., He, D., Huang, T., Lin, H., Yin, H., & Lyu, J. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.976656 · Cited by 4
“In another study on atherosclerotic vascular disease, compared with statins alone, the combination of niacin-laropiprant and statins not only failed to reduce cardiovascular event risk, but also increased the risks of bleeding, infection, and new-onset diabetes (26).”
BackgroundYasmin, F., Ali, S. H., Naeem, A., Savul, S., Afridi, M. S. I., Kamran, N., Fazal, F., Khawer, S., Savul, I. S., Najeeb, H., et al. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2311381 · Cited by 5
“In the Heart Protection Study 2 trial, the niacin group had a similar rate of side effects [65].”
BackgroundImproving Cardiovascular Risk Assessment to Optimize Therapy
Adolphe, A., Wilder, S., Duro, T., Eaton, R. P., & Schade, D. S. (2023) · World Journal of Cardiovascular Diseases · doi:10.4236/wjcd.2023.131002 · Cited by 4
Treatment of Hypercholesterolemia in 2015
Aronow, W. S. (2015) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000358 · Cited by 6
Diabetic Dyslipidemia - Role of Saroglitazar
Majumder, A. (2014) · Medicinal Chemistry · doi:10.4172/2161-0444.1000212 · Cited by 7
“The much larger HPS2-THRIVE (Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events) also failed to show a benefit on clinical outcomes with a different niacin formulation (combined with laropiprant) [25].”
BackgroundDisfunción tiroidea y lipídica asociada a bexaroteno en el linfoma cutáneo de células T
Suárez, S. R., Andreu, E. P., Grijalvo, O. M., & Morillo, J. S. G. (2015) · Medicina Clínica · doi:10.1016/j.medcli.2015.07.017 · Cited by 6
Chan, D. C., Pang, J., & Watts, G. F. (2015) · Springer eBooks · doi:10.1007/978-3-319-12125-3_30-1 · Cited by 7
Donnelly, H. K., Alemayehu, D., Botgros, R., Comic-Savic, S., Eisenstein, B. I., Lorenz, B. D., Merchant, K., Pelfrene, E., Reith, C. A., Santiago, J. F. Y., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw316 · Cited by 4
Egom, E. E. A., Shiwani, H. A., Pharithi, R. B., Canning, R., Khan, B. U., Hiani, Y. E., & Maher, V. M. G. (2017) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12888 · Cited by 4
“Among participants with ASCVD, the addition of extended-release niacin-laropiprant to statin-based LDL-cholesterol-lowering therapy did not significantly reduce the risk of major cardiovascular adverse events but did increase the risk of serious adverse events(16).”
BackgroundChen, S., Wu, H., Yang, T., Li, B., Hu, Y., & Sun, H. (2019) · Cardiovascular Therapeutics · doi:10.1155/2019/1582183 · Cited by 4
Quality over Quantity: A Case Based Review of HDL Function and Dysfunction
Suleiman, S., Coughlan, J. J., & Vincent, M.-H. (2020) · International Journal of Clinical Cardiology · doi:10.23937/2378-2951/1410176 · Cited by 3
Lipoprotein(a) - the cardiovascular risk factor: significance and therapeutic possibilities
Blaha, V. (2018) · Vnitřní lékařství · doi:10.36290/vnl.2018.167 · Cited by 4
Fahed, A. C., & Chae, C. U. (2020) · Springer eBooks · doi:10.1007/978-3-030-45792-1_6 · Cited by 4
Management of Dyslipidaemia in the Elderly
Hamilton‐Craig, I. R., Kostner, K., & Hamilton-Craig, C. R. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_25 · Cited by 4
Omote, K., Yokota, I., Nagai, T., Sakuma, I., Nakagawa, Y., Kamiya, K., Iwata, H., Miyauchi, K., Ozaki, Y., Hibi, K., et al. (2021) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.59881 · Cited by 4
Black, D. M., Miller, M. J., Heinonen, T. M., & Zhang, G. (2021) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001093 · Cited by 4
Ginsberg, H. N., Khavandi, M., & Reyes‐Soffer, G. (2020) · Endocrinology · doi:10.1007/978-3-030-36694-0_2 · Cited by 4
“In the HPS2-Thrive trial, niacin therapy significantly worsened glycemic control in patients with diabetes and induced new onset diabetes in subjects that were non-diabetic [53].”
BackgroundTriglyceride-Rich Lipoproteins, Remnants, and Atherosclerotic Cardiovascular Disease Risk
Bharadiya, V. M., Rawal, S., Jain, V., Chevli, P. A., & Mehta, A. (2022) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-022-00702-1 · Cited by 5
Zhang, P., Ma, J., Li, D., Li, Q., Qi, Z., Xu, P., Liu, L., Li, H., & Zhang, A. (2023) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2023.0101 · Cited by 4
“4 In light of the high-density lipoprotein cholesterol (HDL-C) elevating treatment failure to reduce cardiovascular events, 5 this research focus has shifted to remnant cholesterol (remnant-C), also named triglyceride-rich-lipoprotein (TRL) cholesterol, which is associated with the development of…”
(2000) · Time to knit · doi:10.1016/j.ccol.2015.05.013 · Cited by 4
New worldwide lipid guidelines
Saraf, S., & Ray, K. K. (2015) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000184 · Cited by 4
The future of lipid guidelines
Robinson, J. G. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000355 · Cited by 5
Comparison of Lipid-Lowering Medications and Risk for Cardiovascular Disease in Diabetes
Cavallari, I., Veneri, A. D., Maddaloni, E., Melfi, R., Patti, G., Napoli, N., Pozzilli, P., & Sciascio, G. D. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1117-y · Cited by 4
Tackling Residual Atherosclerotic Risk in Statin-Treated Adults: Focus on Emerging Drugs
Takata, K., & Nicholls, S. J. (2018) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-018-0312-1 · Cited by 4
Orringer, C. E. (2019) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2019.04.009 · Cited by 5
HDL Cholesterol Level and Mortality Occurrence in the Elderly: Is the Good Cholesterol Always Good?
Santos, R. D., & Barter, P. J. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00845 · Cited by 4
Roh, J. W., Chun, K., Kang, M., Lee, C. J., Oh, J., Shim, C. Y., Ahn, C., Kim, J., Kim, B., Park, S., et al. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.06.003 · Cited by 4
Campbell, A. W., Sinatra, D. S., Zhang, Z., & Sinatra, S. T. (2020) · PubMed · Cited by 9
Role of Glucose and Lipids in the Atherosclerotic Cardiovascular Disease of Patients with Diabetes
Feingold, K. R. (2020) · Europe PMC (PubMed Central) · Cited by 5
Lipoprotein and Lipid Metabolism
Hegele, R. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-812535-9.00007-8 · Cited by 8
New and Emerging Therapies for Dyslipidemia
Zambon, A., Averna, M. R., D’Erasmo, L., Arca, M., & Catapano, A. L. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.02.004 · Cited by 5
Hemphill, L. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.09.010 · Cited by 4
PCSK9 Inhibitors: Are We on the Verge of a Breakthrough?
Yang, E. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.263 · Cited by 5
Bays, H. E. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.11.006 · Cited by 4
Changing characteristics of statin-related cIMT trials from 1988 to 2006
Davidson, M. H., Tomassini, J. E., Jensen, E. H., Neff, D., Polis, A. B., & Tershakovec, A. M. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.11.023 · Cited by 4
Refocusing the AIM on HDL in the metabolic syndrome
McGarrah, R. W. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.06.051 · Cited by 4
Management strategies in patients with statin-associated muscle symptoms: What is the best strategy?
JOY, T. R., & Brennan, E. T. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.06.008 · Cited by 4
Randomized controlled trial of different aspirin regimens for reduction of niacin-induced flushing
Banka, S. S., Thachil, R., Levine, A. R., Lin, H. H., Kaafarani, H. M. A., & Lee, J. (2017) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp160219 · Cited by 5
Antisense Oligonucleotides for the Treatment of Hypertriglyceridemia and Hyperlipoproteinemia(a)
Hanßen, R., & Gouni‐Berthold, I. (2017) · Current Pharmacology Reports · doi:10.1007/s40495-017-0115-0 · Cited by 4
“However, the former are not approved for this indication, and nicotinic acid after failing to show positive results in cardiovascular endpoint trials [42, 43] has been removed from many markets and is associated with compliance-limiting side effects, such as flushing.”
BackgroundTop 20 POEMs of the Past 20 Years: A Survey of Practice-Changing Research for Family Physicians
Ebell, M. H., Barry, H. C., Shaughnessy, A. F., Slawson, D. C., Kulkarni, N. S., & Speer, L. (2018) · The Annals of Family Medicine · doi:10.1370/afm.2288 · Cited by 7
Metadata
- Authors
- The HPS2-THRIVE Collaborative Group
- Corresponding author
- The HPS2-THRIVE Collaborative Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-07-17
- Volume
- 371
- Issue
- 3
- Pages
- 203-212
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1856460279
- Cited by
- 1,668
- References
- 33
- Citations by year
- 2026: 72 · 2025: 73 · 2024: 107 · 2023: 113 · 2022: 115 · 2021: 119 · 2020: 132 · 2019: 144 · 2018: 149 · 2017: 159 · 2016: 203 · 2015: 204 · 2014: 71
- FWCI
- 210.23
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- VBN Forskningsportal (Aalborg Universitet) (submittedVersion, other-oa)
- Funders
- Harbin Medical University
- Second Affiliated Hospital of Harbin Medical University
- Cancer Research UK
- National Institute for Health and Care Research (CDF-2013-06-012)
- British Heart Foundation (RE/08/004)
- Tongji University
- Zhengzhou University
- Qingdao University
- First Affiliated Hospital of Zhengzhou University
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- extended-release niacin, laropiprant, LDL cholesterol lowering, HDL cholesterol, major vascular events, secondary prevention, vascular disease, statin therapy, diabetes management, adverse events, cardiovascular risk reduction, lipid-lowering therapy, coronary artery disease, stroke, myocardial infarction, arterial revascularization, infection risk
- MeSH terms
- Aged, Hypolipidemic Agents, Delayed-Action Preparations, Diabetes Mellitus, Double-Blind Method, Drug Combinations, Female, Follow-Up Studies, Hemorrhage, Humans, Hypercholesterolemia, Indoles, Infections, Cholesterol, LDL, Male, Middle Aged, Musculoskeletal Diseases, Niacin, Risk Factors, Treatment Failure, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.